-
2022 v5 NCCN Lung Cancer Guideline: New Options for Neoadjuvant Immunotherapy!
Time of Update: 2022-10-26
【Screenshot of NSCL36 footnote modification】In summary, the update of this guideline marks a new progress in the research of immune checkpoint inhibitors, and the regimen of nivolumab combined with platinum-based dual-agent chemotherapy is likely to become a new standard of neoadjuvant therapy for early resectable NSCLC, igniting new hope for reducing the risk of recurrence and metastasis in postoperative patients.
-
Ann Oncol: Preoperative chemoradiotherapy + minimally invasive surgery has a good effect in the treatment of rectal cancer patients
Time of Update: 2022-10-26
(If you need the original text, you can add Xiaobian WeChat yxj_oncology to obtain) 1Ann Oncol: Preoperative chemoradiotherapy combined with transanal endoscopic minimally invasive surgery for rectal cancer patients has a better effect▎Clinical problems:Total mesenterectomy (TME) is the standard treatment for T2-T3ab, N0, M0 rectal cancer.
-
Professors Li Jianyong, Qiu Lugui and Ji Chunyan jointly explored the refined whole-process management of CLL patients, allowing patients to bloom the "light of life"
Time of Update: 2022-10-26
Chronic lymphoblastic leukemia (CLL) is a subtype of B-cell lymphoma, mainly occurring in middle-aged and elderly people, clinical progress is relatively slow, and heterogeneous, the incidence of CLL
-
2022 SHS| Professor Huang Haiwen: Strive for the best of good, explore the optimization strategy of autologous hematopoietic stem cell transplantation, analyze the characteristic clinical diagnosis and treatment model, and strive to improve the survival and quality of life of lymphoma patients
Time of Update: 2022-10-26
On this occasion, Yimaitong specially invited Professor Huang Haiwen from the First Affiliated Hospital of Soochow University to interpret the application status and future prospects of autologous hematopoietic stem cell transplantation in lymphoma based on clinical experience, so as to feed readers!
-
2022 SHS Professor Tang Xiaowen: AML transplantation needs to pay attention to the whole process management, and myeloid CAR-T treatment has broad prospects
Time of Update: 2022-10-26
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, with an increasing incidence with age and a poor overall prognosis. With the deepening of research, the treatment of AML has
-
Pierce the heart! The taller you are, the greater your risk of cancer! 14% increase for every 10cm height
Time of Update: 2022-10-26
This article is the original of Translational Medicine Network, please indicate the source of reprinting By JevinIt is widely recognized that tall people tend to achieve a state of health after gettin
-
J EUR ACAD DERMATOL: DERMOSCOPY AND CONFOCAL PREDICTIVE DIAGNOSIS OF NONPIGMENTED OR HYPOCHROMIC MALIGNANT LENTIFORM NEVI
Time of Update: 2022-10-26
▎Research protocol:The patient has AHLM/LMM, apigmented or hypochromic benign lesions (AHBL), non-pigmented or hypochromic basal and squamous cell carcinoma (AHBCC/AHSCC) on the head or neck, confirmed by pathological tissue examination by dermoscopy and RCM imaging.
-
2022 SHS Professor Wang Xin: From the perspective of big coffee, the treatment of recurrence after ALL transplantation is explored
Time of Update: 2022-10-26
Acute lymphoblastic leukemia (ALL) is more common in adult hematological malignancies, its treatment prognosis is poor, long-term survival rate is low, although in recent years with the continuous development and application of new drugs, new therapies, ALL treatment efficacy has been rapidly improved, but ALL patients after transplantation recurrence problem is still a major problem in front of hematologists.
-
Professor Wang Xiaojia: Learn from the past, and see how Giredestrant is changing the treatment landscape of HR-positive breast cancer
Time of Update: 2022-10-26
Fig. 2 Changes in ER/PgR protein levels in week 2 of coopERA biomarker subgroup analysis Fig. 3 Results of ER activity score changes in coopERA biomarker subgroup analysisThe acelERA study is a phase II study comparing Giredestrant with physician-selected endocrine monotherapy in patients with previously treated ER+/HER2– locally advanced or metastatic breast cancer (LA/mBC).
-
Research progress of dual-target CAR-T therapy targeting CD19 and CD22 from an international perspective in patients with ALL
Time of Update: 2022-10-26
Trial progress at Stanford University and the National Cancer InstituteStanford University and the National Cancer Institute conducted two phase 1 dose-escalation clinical trials targeting CD19 and CD22 dual-target CAR-T products in adults (NCT03233854) and pediatric patients (NCT03448393) of B-ALL or non-Hodgkin lymphoma (NHL).
-
Vaccination, effective fight cancer! Moderna and Merck jointly develop mRNA personalized cancer vaccines
Time of Update: 2022-10-26
The combination of the two pharmaceutical giants, the dawn of cancer vaccine research and development, Moderna is a famous mRNA vaccine manufacturer in the United States, its therapeutic concept is to use mRNA to make the cells in the patient's body become the "in vivo factory" of drug therapy, focusing on medical key areas including infectious diseases , immuno-oncology, personalized cancer vaccines, rare diseases, cardiovascular diseases, autoimmune diseases.
-
2022 SHS Professor Li Jianyong: Li Chaotou, talk about treatment options for primary central nervous system lymphoma, step on the waves, and discuss the current situation of blood development in Jiangsu
Time of Update: 2022-10-26
The much-anticipated "2022 Suzhou Hematology Summit and National Continuing Medical Education Class" was grandly opened in Suzhou on October 7-9, 2022. The conference invited well-known hematology exp
-
Melanin medullary thyroid cancer, learn about | case sharing
Time of Update: 2022-10-26
Fine needle aspiration biopsy of the right thyroid noduleIn addition, IHC analysis showed that the cells were positive for calcitonin, CEA, synaptophysin, AE1/AE3, CAM5.
Fine needle aspiration biopsy of the right thyroid noduleIn addition, IHC analysis showed that the cells were positive for calcitonin, CEA, synaptophysin, AE1/AE3, CAM5.
-
Professor Yu Zhentao: Aiming at the treatment of pain points, immunotherapy helps the survival of esophageal cancer patients to improve
Time of Update: 2022-10-26
Whether it is the CheckMate series of studies or the Keynote series of studies, we have seen the superiority of immunotherapy in the field of upper gastrointestinal tumor treatment, especially for the high incidence of esophageal squamous cell carcinoma in China, immunotherapy is more effective [5,8]。 In patients with potentially operable locally advanced or esophageal cancer with lymph node metastases, preoperative neoadjuvant CRT regimens recommended by domestic and foreign guidelines as the gold standard.
-
2022 SHS Professor Fu Chengcheng: Jointly build a "blood think tank" and explore a new direction of MM diagnosis and treatment optimization
Time of Update: 2022-10-26
Fu ChengIn the future, MM diagnosis and treatment should take into account standardization and individualization, train clinicians across the country to standardize diagnosis and treatment, and carry out individualized treatment for particularly high-risk patients, including the combination of CAR-T therapy, new monoclonal antibodies or bispecific antibody drugs, so that these patients can obtain better efficacy in the case of poor efficacy of existing therapies.
-
Is MET amplification refractory after EGFR-TKI resistance? Dual targeted therapy with sevotinib combined with osimertinib achieves PR and continues to benefit
Time of Update: 2022-10-26
Dual-target therapy with sevotinib combined with osimertinib brings more treatment opportunities to third-generation EGFR-TKI resistant patientsNon-small cell lung cancer (NSCLC) is the most common type of lung cancer, and epidermal growth factor receptor (EGFR) mutation is the most common type of NSCLC mutated gene, and EGFR-tyrosine kinase inhibitor (TKI) is the first-line standard of care for patients with EGFR-mutated advanced NSCLC.
-
BMJ Magazine: It's a real hammer! Scientists analyzed data from more than 130,000 women and found a causal relationship between increased physical activity and reduced sedentary time and a reduced risk of breast cancer
Time of Update: 2022-10-26
This large Mendelian randomisation (MR) study of more than 130,000 people confirmed that increased physical activity levels and reduced sedentary time reduced breast cancer risk, and for the first time strengthened the causal analysis.
-
【STTT】Tongji University Fang Jianmin et al. discovered a new cell membrane marker for cancer stem cells, targeting it with therapeutic potential!
Time of Update: 2022-10-26
This article is the original of Translational Medicine Network, please indicate the source of reprinting Written by MiaCancer stem cells (CSCs) are thought to be responsible for cancer initiation, gro
-
Blood: Effect of NPM1 and FLT3 mutations on prognosis in patients with AML treated with oral azacitidine
Time of Update: 2022-10-25
In summary, oral azacitidine significantly improved the survival outcomes of patients with acute myeloid leukemia who achieved the first remission after intensive chemotherapy, regardless of NPM1/FLT3 mutation status, cellular risk, and MRD status after intensive chemotherapy.
-
Research Frontiers The number of active surveillance biopsies in patients with this type of PCa can be reduced...
Time of Update: 2022-10-25
Fig. 2 Comparison of the proportion of increased GG grading between the two groupsMultivariate analysis showed a significantly lower risk of switching to aggressive treatment in the biopsy-negative group compared with the initial biopsy-positive result group (HR: 0.
